| 000 | 01660 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517233509.0 | ||
| 264 | 0 | _c20181029 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1432-0851 | ||
| 024 | 7 |
_a10.1007/s00262-018-2224-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNeumann, Frank | |
| 245 | 0 | 0 |
_aDetermination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity. _h[electronic resource] |
| 260 |
_bCancer immunology, immunotherapy : CII _cNov 2018 |
||
| 300 |
_a1709-1718 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xpharmacology |
| 650 | 0 | 4 |
_aAntibody-Dependent Cell Cytotoxicity _ximmunology |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xpharmacology |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aCholecalciferol _xblood |
| 650 | 0 | 4 |
_aCytotoxicity, Immunologic _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKiller Cells, Natural _ximmunology |
| 650 | 0 | 4 | _aLymphocyte Activation |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRituximab _xpharmacology |
| 700 | 1 | _aAcker, Fabian | |
| 700 | 1 | _aSchormann, Claudia | |
| 700 | 1 | _aPfreundschuh, Michael | |
| 700 | 1 | _aBittenbring, Joerg Thomas | |
| 773 | 0 |
_tCancer immunology, immunotherapy : CII _gvol. 67 _gno. 11 _gp. 1709-1718 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00262-018-2224-y _zAvailable from publisher's website |
| 999 |
_c28753853 _d28753853 |
||